摘要
目的探讨Tau蛋白及组蛋白去乙酰化酶1(HDAC1)与肺腺癌患者多西紫杉醇化疗敏感性的关系。方法选取2020年1月至2021年10月间上海市杨浦区控江医院收治的82例肺腺癌患者的临床资料,采用免疫组化法对所有患者的Tau及HDAC1表达水平进行检测,依据Tau及HDAC1表达水平的高低分为Tau低表达组与Tau高表达组、HDAC1低表达组与HDAC1高表达组。所有患者均采用含多西紫杉醇的化疗方案进行新辅助化疗,比较不同组别患者疾病控制率与疾病进展时间。结果82例肺腺癌患者中Tau低表达49例,高表达33例。Tau低表达组患者疾病控制率(77.5%)高于Tau高表达组(51.5%),组间比较,差异有统计学意义(P<0.05)。Tau低表达组患者疾病进展时间为(5.70±1.25)个月,明显高于Tau高表达组的(4.20±1.10)个月,组间差异有统计学意义(P<0.05)。肺腺癌患者中,HDAC1低表达51例,高表达31例。HDAC1低表达组患者疾病控制率(74.5%)高于HDAC1高表达组(48.4%),差异有统计学意义(P<0.05)。HDAC1低表达组患者疾病进展时间为(5.65±1.30)个月,明显高于HDAC1高表达组的(4.25±1.05)个月,差异有统计学意义(P<0.05)。结论低表达的Tau与HDAC1肺腺癌患者采用多西紫杉醇化疗效果较好,患者疾病控制率及疾病进展时间更为理想,临床可以依据肺腺癌患者Tau及HDAC1的表达情况对其化疗敏感性进行预测,为患者预后良好提供科学依据。
Objective To explore the relationship between Tau protein, histone deacetylase 1(HDAC1) and chemosensitivity of docetaxel in patients with lung adenocarcinoma. Methods The clinical data of 82 patients with lung adenocarcinoma admitted to Kongjiang Hospital from January 2020 to October 2021 were retrospectively analyzed. Immunohistochemistry was used to detect the expression levels of Tau and HDAC1 in all patients. Based on the expression levels of Tau and HDAC1, they were divided into low Tau expression group and high Tau expression group, low HDAC1 expression group and high HDAC1 expression group. All patients were treated with docetaxel-containing chemotherapy for neoadjuvant chemotherapy. The disease control rate and disease progression time were compared among patients in different groups. Results Among 82 patients with lung adenocarcinoma, 49 had low Tau expression and 33 had high Tau expression. The disease control rate was 77.5% in low Tau expression group which was significantly higher than 51.5% of high Tau expression group(P<0.05). The disease progression time was 5.70±1.25 months in the low Tau expression group which was significantly higher than 4.20±1.10 months of the high Tau expression group(P<0.05). Of the 82 patients with lung adenocarcinoma, 51 had low expression of HDAC1 and 31 had high expression of HDAC1. The disease control rate of HDAC1 was 74.5% in the low HDAC1 expression group, which was significantly higher than 48.4% of high HDAC1 expression group(P<0.05). Time to disease progression was 5.65±1.30 months in patients in the low HDAC1 expression group which was significantly higher than 4.25±1.05 months of the high HDAC1 expression group(P<0.05). Conclusion Chemotherapy with docetaxel shows good efficacy in patients with low Tau and HDAC1 expressing lung adenocarcinoma with ideal disease control rate and disease progression time. In the clinical practice, the expression of Tau and HDAC1 can be used as factors for the prediction of chemosensitivity of docetaxel for lung adenocarcinoma to provide a scientific basis for a good prognosis of this population.
作者
姜敏敏
张迎
JIANG Min-min;ZHANG Ying(Department of Respiratory,Kongjiang Hospital,Yangpu District,Shanghai 200093,China;Department of Internal Medicine,Kongjiang Hospital,Yangpu District,Shanghai 200093,China)
出处
《中国肿瘤临床与康复》
2022年第10期1169-1173,共5页
Chinese Journal of Clinical Oncology and Rehabilitation
